Psilocybin is a naturally occurring psychedelic compound found in certain species of mushrooms. Once ingested, the body converts psilocybin into psilocin, which interacts primarily with the brain’s serotonin 2A receptors (5-HT2A), a system deeply involved in mood, cognition, memory, and even motor control.

For people with Parkinson’s, psilocybin may offer potential benefits across several areas:

Neuroplasticity:
Psilocybin has been shown to promote neuroplasticity — the brain’s ability to create new neural pathways, repair damaged circuits, and adapt to ongoing challenges. In Parkinson’s, where motor and cognitive circuits are disrupted over time, neuroplasticity may help the brain reorganize and compensate for loss of dopamine-producing neurons.

Neuroinflammation & Oxidative Stress:
Emerging research suggests that psilocybin may have anti-inflammatory and antioxidant properties, which could help reduce the chronic neuroinflammation associated with Parkinson’s progression.

Mood, Anxiety & Depression:
Depression and anxiety are among the most common non-motor symptoms in Parkinson’s, often emerging years before a formal diagnosis. Psilocybin has shown remarkable results in clinical trials for treatment-resistant depression, helping patients experience long-term improvements in emotional well-being and quality of life.

Cognitive Flexibility & Executive Function:
As Parkinson’s progresses, cognitive flexibility — the brain’s ability to switch between tasks, adapt to change, and problem-solve — often becomes impaired. Early studies suggest psilocybin may enhance executive functioning, attention, and learning processes, which are critical for maintaining independence and quality of life.

Processing Trauma & Emotional Regulation:
Parkinson’s can take a significant emotional toll on patients and families. Psilocybin-assisted therapy may help individuals work through grief, fear, identity loss, and emotional trauma associated with chronic illness.

While more research is needed specifically in Parkinson’s patients, early findings across other neurological and psychiatric conditions strongly support the need to explore psilocybin as a potential complementary therapy in the future care of Parkinson’s Disease.

The Parkinson’s Project Foundation fully supports responsible, medically supervised research to better understand psilocybin’s role in neurodegenerative care.

Ibogaine is a plant-derived compound extracted from the root bark of the Tabernanthe iboga shrub, native to West Africa. It has a highly unique pharmacological profile, affecting multiple systems in the brain including:

• Dopamine regulation (relevant to Parkinson’s motor symptoms)

• Serotonin modulation (impacting mood, cognition, and anxiety)

• NMDA receptor modulation (critical for neuroplasticity and cognitive flexibility)

• Sigma receptor activation

• And perhaps most importantly: increased production of neurotrophic factors such as GDNF and BDNF, which may promote nerve repair, neuroprotection, and even regeneration of dopaminergic neurons — the very cells lost in Parkinson’s Disease.

While ibogaine has been most widely studied for addiction and PTSD, its mechanisms suggest potential relevance to neurodegenerative diseases such as Parkinson’s, ALS, and MS.

No. As of now, both psilocybin and ibogaine remain investigational therapies for Parkinson’s and are not FDA-approved treatments for neurodegenerative diseases.

However, research is actively expanding:

Psilocybin:

• Multiple Phase II and Phase III clinical trials are underway for depression, anxiety, PTSD, and trauma-related disorders.

• In Parkinson’s specifically, early research is being conducted at academic centers — including Johns Hopkins, NYU, and UCSF — investigating psilocybin’s potential role in addressing anxiety, depression, cognition, quality of life, and neuroplasticity in patients living with Parkinson’s Disease.

• While these studies are still in early phases, they represent an important step toward understanding how psilocybin may impact both motor and non-motor symptoms in Parkinson’s care.

Ibogaine:

• Historically studied for addiction and PTSD, ibogaine is now entering early-stage clinical trials to explore its unique neuroregenerative potential.

• Some organizations are leading new research efforts specifically targeting neurodegenerative diseases, including Parkinson’s, ALS, TBI, and others.

The Parkinson’s Project Foundation remains committed to supporting responsible, medically supervised research into these emerging therapies — always guided by science, safety, and ethical care.

In most of the United States, both ibogaine and psilocybin remain Schedule I substances at the federal level.

• Some states and cities have decriminalized psilocybin for personal use.

• Ibogaine remains more restricted and is only being administered legally in specific research trials or international medical clinics.

• Texas (through SB 2308) has recently allocated $50 million to fund ibogaine clinical research—marking one of the most significant developments in psychedelic medicine policy to date.

At this time, The Parkinson’s Project Foundation does not provide or facilitate access to these therapies.

Because traditional treatment options for Parkinson’s focus largely on managing symptoms without addressing the underlying neurodegeneration. Many plant-based and psychedelic compounds work through entirely different mechanisms that may offer:

• Neuroplasticity

• Cognitive protection

• Mood regulation

• Neurotrophic growth

• Reduction in neuroinflammation

• Potential support for slowing or modifying disease progression itself

Our mission is to advocate for safe, ethical, science-based exploration of these emerging options, while ensuring patients have truthful, responsible education — not hype or misinformation.

At this time, no. We are not a treatment provider, and we do not directly facilitate access to ibogaine, psilocybin, or any other investigational therapy.

However, we are actively:

• Building partnerships with clinical organizations, research institutions, and trusted providers who are leading legal, medically supervised programs.

• Raising funds to develop a patient grant program that, once fully funded and legally structured, will help eligible patients access these therapies safely and responsibly through approved clinical channels.

• Educating patients so they are fully informed as these therapies become more widely available through regulated research and clinical care.

Our goal is to create safe, responsible pathways for patients to access these therapies when legally possible—always with proper medical oversight, ethical standards, and full transparency.

We do not recommend seeking any illegal or underground treatments.

Both ibogaine and psilocybin carry unique risks and require appropriate medical oversight to ensure safety, especially in patients with complex medical conditions such as Parkinson’s, cardiovascular issues, or psychiatric history.

We advocate for:

• Medically supervised programs

• Thorough screening protocols

• Legal compliance

• Ethical and science-based care

Participation in ongoing clinical trials when available

There are several ways to join us in this mission:

• Stay Informed: Follow our educational content, webinars, and updates as research continues to evolve.

• Help Fund Our Work: As a nonprofit, we rely on donations, partnerships, and corporate support to fund educational resources, advocacy efforts, and the future launch of our patient grant program.

• Advocate for Policy Change: One of the most powerful ways individuals can contribute is by supporting legislative efforts to expand research and legal access to plant-based and psychedelic therapies. Contacting your state legislators, attending public hearings, sharing patient stories, and advocating for research funding are critical steps toward making these therapies legally and safely available to those who need them.

• Share Your Story: Patient voices are powerful. Sharing your experience helps educate others, reduce stigma, and push this conversation forward.

Together, we can change the way Parkinson’s—and all neurodegenerative diseases—are understood, researched, and treated.